Drug Trial Radar · NCT05415215
A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer
Last checked: Nov 20, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
346
Actual
Start
Jul 5, 2022
Primary completion
Nov 20, 2024
Study completion Nov 7, 2025
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jun 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase IIIb, multinational, multicenter, randomized, open-label study to evaluate patient preference of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous use (PH FDC SC) administration in the home setting compared with the hospital setting during the cross-over period of adjuvant treatment in participants with early or locally advanced/inflammatory human epidermal growth factor receptor 2-positive (HER2+) breast cancer.
Conditions
- Early Breast Cancer
- Locally Advanced Breast Cancer
- Inflammatory Breast Cancer
Interventions
Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)Drug
PH FDC SC is administered subcutaneously (SC) as a fixed non-weight-based dose. A loading dose of 1200 milligram (mg) pertuzumab, 600 mg trastuzumab, and 30,000 units of recombinant human PH20 hyaluronidase (rHuPH20) is given in the first cycle (1 cycle is 21 days). In subsequent cycles, maintenance doses of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units rHuPH20 are administered once every 3 weeks (Q3W).
Pertuzumab IVDrug
Pertuzumab is given as a fixed dose of 840 mg intravenous (IV) loading dose and then 420 mg IV for subsequent maintenance doses once every 3 weeks.
Trastuzumab IVDrug
Trastuzumab is given as an 8 milligram per kilogram (mg/kg) intravenous (IV) loading dose and then 6 mg/kg IV for subsequent maintenance doses once every 3 weeks.
Trastuzumab EmtansineDrug
Trastuzumab emtansine will be given at a dose of 3.6 mg/kg by intravenous (IV) infusion, once every 3 weeks.
Investigator's Choice of ChemotherapyDrug
Option 1: Docetaxel and carboplatin once every 3 weeks for 6 cycles; Option 2: Doxorubicin plus cyclophosphamide once every 3 weeks for 4 cycles, followed by a taxane (docetaxel once every 3 weeks for 4 cycles or paclitaxel once every week for 12 cycles); Option 3: Dose-dense doxorubicin plus cyclophosphamide (ddAC) once every 2 weeks for 4 cycles, followed by a taxane (docetaxel once every 3 weeks for 4 cycles or paclitaxel once every week for 12 cycles).
SurgeryProcedure
After completing their neoadjuvant therapy, participants will undergo surgical resection for early or locally advanced HER2+ breast cancer (if eligible for surgery). Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice. The surgery cannot be performed ≤2 weeks from the last systemic neoadjuvant therapy and must be performed ≤6 weeks after the last systemic neoadjuvant therapy.
RadiotherapyRadiation
After surgery, radiotherapy is to be given as clinically indicated and as per local practice or institutional standards. The selected radiotherapy regimen should be initiated within 4 weeks after surgery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cross-over Period: Percentage of Participants Who Preferred the Administration of PH FDC SC in the Home Setting Compared With the Hospital Setting in Question 1 of the Patient Preference Questionnaire (PPQ)Time frame: Upon completion of adjuvant cross-over period (Day 1 of Cycle 8 or 9; Cycle length = 21 days)
Locations
45 sites in 17 countries. Site status is shown where the registry gives one.
Centro Oncologico Korben
Ciudad Autonoma Buenos Aires, Argentina
Centro de Investigaciones Médicas y Desarrollo LC S.R.L
Buenos Aires, Ciudad Autónoma de BuenosAires, Argentina
University Clinical Center of the Republic of Srpska
Banja Luka, Bosnia and Herzegovina
Cantonal Hospital Zenica
Zenica, Bosnia and Herzegovina
Crio - Centro Regional Integrado de Oncologia
Fortaleza, Ceará, Brazil
Hospital Araujo Jorge
Goiânia, Goiás, Brazil
Hospital Nossa Senhora da Conceicao
Porto Alegre, Rio Grande do Sul, Brazil
Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda
São Paulo, São Paulo, Brazil
Multiprofile Hospital for Active Treatment Uni Hospital
Panagyurishte, Bulgaria
Complex Oncology Center - Plovdiv First Internal Chemotherapy Department
Plovdiv, Bulgaria
MHAT Nadezhda
Sofia, Bulgaria
Royal Victoria Regional Health Centre
Barrie, Ontario, Canada
Lakeridge Health Oshawa
Oshawa, Ontario, Canada
North York General Hospital
Toronto, Ontario, Canada
Jewish General Hospital
Montreal, Quebec, Canada
Hopital du Saint Sacrement
Québec, Quebec, Canada
Clinica Vespucio
Santiago, Chile
Centro de Estudios Clínicos SAGA
Santiago, Chile
Clinica CIMCA
San José, Costa Rica
ICIMED Instituto de Investigación en Ciencias Médicas
San José, Costa Rica
Hospital Metropolitano (Sede Lindora-Santa Ana)
San José, Costa Rica
Clinical Hospital Centre Zagreb
Zagreb, Croatia
Saifee Hospital
Mumbai, Maharashtra, India
TATA Medical Centre
Kolkata, West Bengal, India
International Cancer Institute (ICI)
Eldoret, Kenya
The Aga Khan University-Kenya.
Nairobi, Kenya
Iem-Fucam
D.F., Mexico City, Mexico
Health Pharma Professional Research
Mexico City, Mexico City, Mexico
Oncologico Potosino
San Luis Potosí City, San Luis Potosí, Mexico
Instituto Regional de Enfermedades Neoplásicas del Sur
Arequipa, Peru
Oncocenter Peru S.A.C.
Lima, Peru
National Cancer Centre
Singapore, Singapore
Tan Tock Seng Hospital
Singapore, Singapore
Medical Oncology Centre of Rosebank
Johannesburg, South Africa
Wilgers Oncology Centre
Pretoria, South Africa
Korea University Anam Hospital
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico
Jaén, Spain
Hospital Universitario Virgen de Arrixaca
Murcia, Spain
Hospital Clinico Universitario de Salamanca
Salamanca, Spain
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.